Atlas Trials

Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation

Clinical trial NCT04399980 · COMPLETED

Trial details

NCT number
NCT04399980
Sponsor
The Cleveland Clinic
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
COVID 19SARS-CoV 2Pneumonia
Start date
2020-05-20
Primary completion
2021-04-23
Enrollment
40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.